Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Denmark
  4. Nasdaq Copenhagen
  5. ViroGates A/S
  6. News
  7. Summary
    VIRO   DK0061030574

VIROGATES A/S

(VIRO)
SummaryQuotesChartsNewsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Frontiers in Immunology publication: Soluble Urokinase Plasminogen Activator Receptor (suPAR) as a Biomarker of Systemic Chronic Inflammation

12/03/2021 | 09:52am EST

Systemic chronic inflammation (SCI) is persistent, health-damaging, low-grade inflammation that plays a major role in immunosenescence and in the development and progression of many diseases. But currently, there are no recognized standard biomarkers to assess SCI levels alone, and SCI is typically measured by combining biomarkers of acute inflammation and infection, e.g., CRP, IL‐6, and TNFα.

In this review, we highlight 10 properties and characteristics that are shared by the blood protein soluble urokinase plasminogen activator receptor (suPAR) and SCI, supporting the argument that suPAR is a biomarker of SCI:
1. Expression and release of suPAR is upregulated by immune activation;
2. uPAR and suPAR exert pro-inflammatory functions;
3. suPAR is associated with the amount of circulating immune cells;
4. Blood suPAR levels correlate with the levels of established inflammatory biomarkers;
5. suPAR is minimally affected by acute changes and short-term influences, in contrast to many currently used markers of systemic inflammation;
6. Like SCI, suPAR is non-specifically associated with multiple diseases;
7. suPAR and SCI both predict morbidity and mortality;
8. suPAR and SCI share the same risk factors;
9. suPAR is associated with risk factors and outcomes of inflammation above and beyond other inflammatory biomarkers;
10. The suPAR level can be reduced by anti-inflammatory interventions and treatment of disease.

Assessing SCI has the potential to inform risk for morbidity and mortality. Blood suPAR is a newer biomarker that may, in fact, be a biomarker of SCI since it is stably associated with inflammation and immune activation; shares the same risk factors as many age-related diseases; is both elevated by and predicts age-related diseases. There is strong evidence that suPAR is a prognostic marker of adverse events, morbidity, and mortality. It is associated with immune activity and prognosis across diverse conditions, including kidney disease, cardiovascular disease, cancer, diabetes, and inflammatory disorders. Thus, we think it likely represents a common underlying disease-process shared by many diseases; that is, SCI.

Disclaimer

ViroGates A/S published this content on 03 December 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 03 December 2021 14:51:05 UTC.


ę Publicnow 2021
All news about VIROGATES A/S
01/11NATURE MEDICINE PUBLICATION : Early anakinra treatment for COVID-19 guided by suPAR saves ..
PU
2021ViroGates publishes the financial calendar for 2022
AQ
2021ViroGates on positive EMA opinion regarding suPAR-guided anakinra treatment (Video)
AQ
2021ViroGates announces a positive opinion from the CHMP of the EMA for suPAR-guided anakin..
AQ
2021ViroGates Announces Positive Opinion from the CHMP of the EMA for suPAR-Guided Anakinra..
CI
2021VIROGATES A/S : SuPAR independently predicts severity and length of hospitalisation in pat..
PU
2021ViroGates announces a development, supply and collaboration agreement with Italy-based ..
AQ
2021FRONTIERS IN IMMUNOLOGY PUBLICATION : Soluble Urokinase Plasminogen Activator Receptor (su..
PU
2021ViroGates awarded a 2.8 DKKm Innobooster grant by The Innovation Fund Denmark to finali..
AQ
2021NATURE MEDICINE PUBLICATION : Early anakinra treatment for COVID-19 guided by suPAR saves ..
PU
More news
Financials
Sales 2020 5,35 M 0,82 M 0,82 M
Net income 2020 -18,7 M -2,87 M -2,87 M
Net cash 2020 33,5 M 5,14 M 5,14 M
P/E ratio 2020 -13,4x
Yield 2020 -
Capitalization 507 M 77,7 M 77,7 M
EV / Sales 2019 17,5x
EV / Sales 2020 41,3x
Nbr of Employees 14
Free-Float -
Chart VIROGATES A/S
Duration : Period :
ViroGates A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VIROGATES A/S
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Managers and Directors
Jakob Knudsen Chief Executive Officer
Mark Christian Hvidberg da Silva Chief Financial Officer
Lars Kongsbak Chairman
Jesper Eugen-Olsen Chief Scientific Officer
J÷rgen Axel Thorball Director
Sector and Competitors